BioNTech's Seoul Readout Meets a Skeptical Street
Published on 09/11/2026 at 11:41 | Editorial boerse-global.de
BioNTech investors are heading into one of the more consequential stretches of the company's post-pandemic story, and the setup is anything but clean. Between September 12 and 15, the Mainz-based biotech will roll out fresh clinical data at the IASLC World Conference on Lung Cancer in Seoul, putting its oncology pipeline under a spotlight that has grown considerably harsher in recent weeks.
The centerpiece is pumitamig, a bispecific antibody targeting PD-L1 and VEGF-A that has become the company's most closely watched pipeline asset. For the first time, BioNTech plans to unveil global data on pairing pumitamig with elfetabart drozuntecan, an antibody-drug conjugate, from a Phase 1/2 trial in advanced or metastatic small-cell and non-small-cell lung cancer. Alongside that, the company will present updated survival results from the Phase 3 PRESERVE-003 study of gotistobart in patients with squamous cell carcinoma whose disease had progressed after a PD-(L)1 therapy.
A downgrade that landed first
The data drop arrives against a backdrop of already frayed analyst sentiment. On September 8, BMO Capital cut BioNTech to Market Perform from Outperform, trimming its price target to $105 from $128. The brokerage pointed to a steeper-than-expected decline in Comirnaty sales and the absence of "de-risking data" for pumitamig, which its analysts don't expect to materialize until 2028.
That skepticism sits awkwardly next to the Seoul agenda. BioNTech wants to show early efficacy signals; BMO is effectively arguing that the kind of evidence needed to underwrite the investment case remains years away. For shareholders, the practical takeaway is that the conference data will likely set direction rather than settle the debate.
A setback in colorectal cancer
Feeding the cautious mood is BioNTech's decision in late August to halt a Phase 2 study of autogene cevumeran in colorectal cancer. The individualized mRNA cancer therapy, developed with Roche's Genentech, had been slated for testing as an adjuvant monotherapy in patients with resectable Stage II or Stage III colorectal cancer.
Should investors sell immediately? Or is it worth buying BioNTech?
An independent data monitoring committee flagged an imbalance in overall survival and concluded that continuing the trial would probably not change the efficacy readout. BioNTech was quick to note that a separate study, IMcode003, which tests autogene cevumeran in ductal pancreatic cancer alongside Genentech, remains untouched and is proceeding as planned. Even so, the discontinuation is a reminder that not every bet in a broad oncology pipeline pays off — and it raises the stakes for what pumitamig and gotistobart show in Seoul.
Reading the insider trade correctly
Around the same time, market watchers flagged that CEO Ugur Sahin had sold 37,000 shares. Taken in isolation, the move invites an obvious narrative: a chief executive offloading stock shortly after a key trial collapsed and the revenue outlook was trimmed.
That reading doesn't hold up. The sales were executed under a Rule 10b5-1 trading plan Sahin put in place on June 3 — well before the revenue guidance was cut in early August and before the colorectal trial was terminated in late August. Such pre-arranged plans are typically used for diversification and run automatically on a fixed schedule, regardless of what news breaks later. Treating them as timing signals mistakes a bureaucratic mechanism for a deliberate call. At biotech companies with complex compensation structures and long-term equity programs, scheduled sales are the norm, not the exception.
The numbers behind the caution
The revenue picture explains much of the wariness. BioNTech lowered its full-year 2026 guidance to EUR 1.6 billion to EUR 1.9 billion, down from a prior range of EUR 2.0 billion to EUR 2.3 billion, citing weaker global demand for Covid vaccines and inventory reductions in Germany. That revision is the backdrop against which BMO's September 8 downgrade — and its $105 target, down from $128 — should be read.
Trading has reflected the mixed flow of news without committing to a direction. The stock recently changed hands at EUR 84.25, up 1.4% on the day, and sits close to both its 50-day moving average of EUR 84.09 and its 200-day average of EUR 84.17 — a picture of indecision that mirrors the conflicting headlines. Over the past seven days the shares have shed 5.7%, though they are up 4.7% on a monthly basis. Earlier in the week, the stock was quoted at EUR 83.55, roughly 21% below its 52-week high of EUR 105.80 reached in January, with a 6.5% decline over seven days.
What Seoul has to prove
The question facing investors isn't whether Sahin has lost faith in his own company — the scheduled share sale offers no evidence of that. It is whether the oncology pipeline, which carries BioNTech's long-term story, still has enough substance after the autogene cevumeran setback in colorectal cancer. The ongoing pancreatic cancer trial with Genentech provides at least one live test, though its outcome won't be known for some time.
Nearer term, everything hinges on how robust the survival and efficacy data presented in Seoul turn out to be. A positive surprise on pumitamig and gotistobart could steady a bruised sentiment. Should the results fall short of expectations, the analysts' doubts will only find more to feed on.
Ad
BioNTech Stock: New Analysis - 11 September
Fresh BioNTech information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
